Boothbay Fund Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.13M | Buy |
16,932
+14,132
| +505% | +$1.78M | 0.04% | 359 |
|
|
2025
Q1 | $310K | Buy |
+2,800
| New | +$310K | 0.01% | 894 |
|
|
2024
Q4 | – | Sell |
-2,337
| Closed | -$269K | – | 1579 |
|
|
2024
Q3 | $269K | Sell |
2,337
-8,983
| -79% | -$1.04M | 0.01% | 1115 |
|
|
2024
Q2 | $1.56M | Buy |
+11,320
| New | +$1.56M | 0.04% | 491 |
|
|
2023
Q2 | – | Sell |
-36,624
| Closed | -$3.71M | – | 1866 |
|
|
2023
Q1 | $3.71M | Buy |
+36,624
| New | +$3.71M | 0.08% | 316 |
|
|
2022
Q3 | – | Sell |
-4,273
| Closed | -$417K | – | 2176 |
|
|
2022
Q2 | $417K | Buy |
+4,273
| New | +$417K | 0.01% | 1108 |
|
|
2022
Q1 | – | Sell |
-17,272
| Closed | -$1.47M | – | 2086 |
|
|
2021
Q4 | $1.47M | Buy |
17,272
+14,233
| +468% | +$1.21M | 0.03% | 503 |
|
|
2021
Q3 | $291K | Sell |
3,039
-393
| -11% | -$37.6K | 0.01% | 1129 |
|
|
2021
Q2 | $334K | Buy |
+3,432
| New | +$334K | 0.01% | 1070 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 1475 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 1212 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 937 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 887 |
|
|
2019
Q4 | – | Sell |
-29,100
| Closed | -$2.62M | – | 851 |
|
|
2019
Q3 | $2.62M | Buy |
+29,100
| New | +$2.62M | 0.24% | 80 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 740 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 745 |
|
|
2018
Q1 | – | Sell |
-4,190
| Closed | -$325K | – | 704 |
|
|
2017
Q4 | $325K | Buy |
+4,190
| New | +$325K | 0.05% | 341 |
|